Acute Otitis MediaPARENT-EARNCT07640568
Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging
A study testing Assigning of a digital otoscope to the families in the intervention group in people with Acute Otitis Media and Otitis Media, run by Turku University Hospital at 2 sites in Finland.
Trial summary
Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on… Read more about this study
- Who is it for?
- Ages 12 to 47 monthsHealthy volunteers can take part
- Conditions the study is for
- Acute Otitis Media, Otitis Media
- What is being tested?
- Assigning of a digital otoscope to the families in the intervention group
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 2 sitesFinland
- Study dates
- 1 Sep 2026to 31 Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 47 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- At least one episode of AOM within the last 12 months
- Family speaks fluent Finnish
Who cannot join
- Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy
- Middle ear fluid at the time of recruitment
- Previously diagnosed hearing loss
- Immunosuppressive disorder or medication, excluding inhaled corticosteroids
- Anatomic defect or anomaly affecting the susceptibility to AOM
- Previous otoscopy experience of the participating parent
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Finland2 sites, 2 recruiting
- Not yet recruiting
Turku University Hospital
Turku, Southwest Finland, 20521
Paula A Tähtinen, MD, PhD, +35823130000, paula.tahtinen@utu.fi
Lotta E Ivaska, MD, PhD, +35823130000, lesaar@utu.fi
- Recruiting
Vaasa Central Hospital
Vaasa, Pohjanmaa, 65130
Simo Nuuttila, MD, +358503314426, simo.c.nuuttila@utu.fi
Lisa Kulppi, MD, +35862181111, lisa.kulppi@ovph.fi
About this study
Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.
Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.
Read more
The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.
Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).
Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.
Intervention group:
Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.
Control group:
Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.
Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.
This is a pilot study with a target sample size of 20 children per arm, limited by device availability.
Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.
The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.
Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.
All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.
- Conditions
- Acute Otitis Media, Otitis Media
- Being tested
- Assigning of a digital otoscope to the families in the intervention group
- Keywords
- acute otitis media, otitis media, digital otoscopy, telemedicine
- Medical subject headings
- Otitis Media
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Assigning of a digital otoscope to the families in the intervention groupDevice
Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Intervention group to receive the digital otoscope Receives: Device: Assigning of a digital otoscope to the families in the intervention group |
| Control group | No intervention | Control group with no intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of physician visits due to suspected AOM
Number of physician visits due to suspected AOM
Measured: 5 to 9 months, depending on date of recruitment
Secondary outcomes (7)
Agreement between parent interpretation, AI classifier, and expert gold standard
Parent's interpretation of the tympanic membrane image is retrospectively compared to the expert's gold standard and classification by an artificial intelligence classifier
Measured: 5 to 9 months, depending on date of recruitment
Antibiotic prescription rates
Antibiotic prescription rates for AOM in both arms
Measured: 5 to 9 months, depending on date of recruitment
Adverse events related to otoscopy
Adverse events, such as abrasion, related to otoscopy in the experimental group
Measured: 5 to 9 months, depending on date of recruitment
AOM-related complications
AOM-related complications, such as mastoiditis, in both arms
Measured: 5 to 9 months, depending on date of recruitment
Daycare absence
Child's absence from daycare due to suspected AOM
Measured: 5 to 9 months, depending on date of recruitment
Parental work absenteeism
Parental work absenteeism due to suspected AOM
Measured: 5 to 9 months, depending on date of recruitment
Parental satisfaction on a visual analog scale (VAS)
Parental satisfaction in the experimental group of AOM management with parent-led digital otoscopy
Measured: 5 to 9 months, depending on date of recruitment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2026
- Study start1 Sep 2026
- Primary completion31 May 2027 (estimated)
- Study completion31 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Otitis MediaStudies of the same condition, open and under way.
- More trials run by Turku University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Turku University Hospital
- Sponsor type
- Other government
- Collaborators
- Vaasa Central Hospital, Vaasa, Finland
- Responsible party
- Principal investigator, Paula Tähtinen, Turku University Hospital
- Investigators
- Paula A Tähtinen, MD, PhD, Principal investigator, Department of Paediatiatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Finland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07640568
- Sponsor's protocol ID
- VARHA/4418/13.02.01/2026
- Acronym
- PARENT-EAR
- Status last verified
- Sep 2026
- First submitted
- 27 May 2026
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified participant data will be made available upon reasonable request from the corresponding author.
Publications
Nuuttila S, Vallin A, Klockars T, Ruohola A, Laine M, Ivaska LE, Tahtinen PA. An artificial intelligence classifier as a screening tool to rule out otitis media in children. Int J Pediatr Otorhinolaryngol. 2026 Jun;205:112847. doi: 10.1016/j.ijporl.2026.112847. Epub 2026 May 9.
PubMed 42114455
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Parent-led Assessment and Recognition of AOM Using Digital Ear Imaging
- ClinicalTrials.gov ID
- NCT07640568
- Acronym / sponsor ID
- PARENT-EAR / VARHA/4418/13.02.01/2026
- Conditions
- Acute Otitis Media, Otitis Media
- Keywords
- acute otitis media, otitis media, digital otoscopy, telemedicine
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Turku University HospitalOther government
- Collaborators
- Vaasa Central Hospital, Vaasa, Finland
- Study start
- 1 Sep 2026 (actual)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 31 Aug 2027 (estimated)
- First posted
- 10 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Acute otitis media (AOM) is the most common bacterial infection in young children and a major contributor to healthcare utilization and costs. Diagnosis relies on otoscopy and identification of tympanic membrane (TM) bulging, yet physician-performed otoscopy has variable diagnostic accuracy and depends heavily on clinical expertise.
Digital otoscopy combined with artificial intelligence (AI)-based image analysis has demonstrated high diagnostic accuracy in previous studies. In a recent study by our group, digital otoscopy with an automated neural network classifier reliably ruled out otitis media in children.
The PARENT-EAR randomized controlled pilot trial aims to evaluate whether parent-performed digital otoscopy at home, combined with retrospective AI analysis of captured TM images, can reduce physician visits due to suspicion of AOM. The study also assesses feasibility, diagnostic accuracy of parents after training, and potential effects on antibiotic use and healthcare utilization.
Methods and outcomes The PARENT-EAR trial is a randomized controlled pilot trial conducted at Vaasa Central Hospital and Turku University Hospital. Recruitment will occur between September and December 2026 (extended if necessary), with follow-up ending May 31, 2027 (5-9 months per participant).
Children aged 12 to 47 months with at least one AOM episode in the past 12 months will be randomized 1:1 using permuted block randomization. Exclusion criteria include tympanostomy tubes, tympanic membrane perforation, middle ear effusion at recruitment, immunosuppression, previously diagnosed hearing loss or anatomical abnormalities predisposing to AOM, and otoscopy experience of the parent.
Intervention group:
Parents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed.
Control group:
Standard care without home otoscopy. Parents complete the same symptom diary and seek care according to usual practice.
Statistical analyses will compare outcomes between groups. AI-based TM classification will be compared against expert panel evaluation.
This is a pilot study with a target sample size of 20 children per arm, limited by device availability.
Ethical aspects, data collection and handling The study will be conducted in accordance with the Declaration of Helsinki. Written informed consent will be obtained from all parents after provision of oral and written information. Participation is voluntary, and families may withdraw at any time. Investigators may discontinue participation if deemed in the child's best interest.
The digital otoscope is a CE-marked Class I medical device used solely for visual inspection of the tympanic membrane. Pneumatic pumps are not provided. Potential risks include minor ear canal abrasions or discomfort; serious adverse events are considered rare. Any adverse events will be managed according to standard clinical practice and reported to relevant authorities when required. The study is investigator-initiated. The device manufacturer provides the otoscopes but has no role in study design, data access, or analysis.
Data will be collected via paper symptom diaries, monthly REDCap questionnaires (University of Turku), and national electronic health records (Kanta). TM images and videos will be securely stored and imported into a research database with relevant metadata.
All data will be handled in accordance with the EU General Data Protection Regulation (GDPR 2016/679). Study data will be pseudonymized and identified only by study ID numbers. The key linking personal identifiers to study IDs will be stored separately and securely. Paper diaries will be destroyed after digitalization. Consent includes permission to access health records and to use collected images and data for scientific purposes. Results will be published in peer-reviewed journals and as part of a doctoral thesis.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Device: Assigning of a digital otoscope to the families in the intervention groupIntervention group to receive the digital otoscope |
| Control group | No intervention | –Control group with no intervention |
Who may qualify
- Ages
- 12 to 47 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- At least one episode of AOM within the last 12 months
- Family speaks fluent Finnish
Key exclusion criteria (6 listed)
- Tympanostomy tubes or perforation of the TM, or scheduled for upcoming tympanostomy
- Middle ear fluid at the time of recruitment
- Previously diagnosed hearing loss
- Immunosuppressive disorder or medication, excluding inhaled corticosteroids
- Anatomic defect or anomaly affecting the susceptibility to AOM
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Assigning of a digital otoscope to the families in the intervention groupParents receive a digital otoscope (The Ear Puffin by Sibbo Medical Devices, MDR EU Class I device) and training on TM image interpretation. They complete a TM image classification quiz before and after the training. During follow-up, parents perform home otoscopy when suspecting AOM, capture TM images/videos, interpret findings, and record symptoms in a diary. If AOM is suspected or the child appears ill, medical evaluation is instructed. | Device | Intervention group |
Primary outcome
Number of physician visits due to suspected AOM
Time frame: 5 to 9 months, depending on date of recruitment
Number of physician visits due to suspected AOM
7 secondary outcomes
Agreement between parent interpretation, AI classifier, and expert gold standard
Time frame: 5 to 9 months, depending on date of recruitment
Antibiotic prescription rates
Time frame: 5 to 9 months, depending on date of recruitment
Adverse events related to otoscopy
Time frame: 5 to 9 months, depending on date of recruitment
AOM-related complications
Time frame: 5 to 9 months, depending on date of recruitment
Daycare absence
Time frame: 5 to 9 months, depending on date of recruitment
Parental work absenteeism
Time frame: 5 to 9 months, depending on date of recruitment
Parental satisfaction on a visual analog scale (VAS)
Time frame: 5 to 9 months, depending on date of recruitment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Background: PubMed 42114455Nuuttila S, Vallin A, Klockars T, Ruohola A, Laine M, Ivaska LE, Tahtinen PA. An artificial intelligence classifier as a screening tool to rule out otitis media in children. Int J Pediatr Otorhinolaryngol. 2026 Jun;205:112847. doi: 10.1016/j.ijporl.2026.112847. Epub 2026 May 9.
- Individual participant dataSharing planned: Yes. Deidentified participant data will be made available upon reasonable request from the corresponding author.
Related trials for Acute Otitis Media
Active, not recruiting
In-Office Clinical Study of the Solo+ TTD
Ear Infection, Otitis Media
Recruiting
CLIKX® Tympanostomy Tube Delivery System for the Placement of Tympanostomy Tubes
Otitis Media, Otitis Media Chronic
Not yet recruiting
Short-term Application of Lactoferrin Ventilation Tubes
Otitis Media With Effusion (OME)
Recruiting
Nasopharyngeal Carriage of S. Pneumoniae
Nasopharyngeal Carriage, Children, Only
Recruiting
Platelet-Rich Fibrin in Revision Cartilage Tympanoplasty
Tympanic Membrane Perforation, Chronic Otitis Media
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Paula A Tähtinen, MD, PhD principal investigator
Department of Paediatiatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Finland
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Assigning of a digital otoscope to the families in the intervention group in people with Acute Otitis Media and Otitis Media, run by Turku University Hospital at 2 sites in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Simo Nuuttila, MD (+358503314426, simo.c.nuuttila@utu.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of physician visits due to suspected AOM (time frame: 5 to 9 months, depending on date of recruitment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07640568, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.